JP2009542708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542708A5 JP2009542708A5 JP2009518465A JP2009518465A JP2009542708A5 JP 2009542708 A5 JP2009542708 A5 JP 2009542708A5 JP 2009518465 A JP2009518465 A JP 2009518465A JP 2009518465 A JP2009518465 A JP 2009518465A JP 2009542708 A5 JP2009542708 A5 JP 2009542708A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- diazepan
- methanone
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 83
- -1 —OH Chemical group 0.000 claims 79
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 25
- 208000035475 disorder Diseases 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 208000026139 Memory disease Diseases 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 206010024264 Lethargy Diseases 0.000 claims 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims 2
- 206010041349 Somnolence Diseases 0.000 claims 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- GNTOQRRKRNHLBL-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CCC2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 GNTOQRRKRNHLBL-UHFFFAOYSA-N 0.000 claims 1
- AJJXEACVSPXKMS-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(3,4-dichlorophenoxy)-4-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC=C(C(=O)N2CCN(CCC2)C2CC2)C=C1OC1=CC=C(Cl)C(Cl)=C1 AJJXEACVSPXKMS-UHFFFAOYSA-N 0.000 claims 1
- HASNZFFRDSPBMJ-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-(3-methyl-4-methylsulfanylphenoxy)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(SC)C(C)=C1 HASNZFFRDSPBMJ-UHFFFAOYSA-N 0.000 claims 1
- DGRXLTADUFHHBN-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-(4-methylsulfanylphenoxy)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(SC)C=C1 DGRXLTADUFHHBN-UHFFFAOYSA-N 0.000 claims 1
- IRQHEXHOAZGQDN-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-(6-methylpyridin-3-yl)oxyphenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(C)N=C1 IRQHEXHOAZGQDN-UHFFFAOYSA-N 0.000 claims 1
- WRACQGSYQITGPK-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-[2-(trifluoromethoxy)phenoxy]phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC=C1OC(F)(F)F WRACQGSYQITGPK-UHFFFAOYSA-N 0.000 claims 1
- BPYJWNTUBNVSJN-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-[2-(trifluoromethyl)phenoxy]phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC=C1C(F)(F)F BPYJWNTUBNVSJN-UHFFFAOYSA-N 0.000 claims 1
- DMKNBJGZUPGVEW-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-[4-(trifluoromethyl)phenoxy]phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(C(F)(F)F)C=C1 DMKNBJGZUPGVEW-UHFFFAOYSA-N 0.000 claims 1
- JTTOIYGKVCKBNW-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-[4-(trifluoromethyl)pyridin-2-yl]sulfanylphenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1SC1=CC(C(F)(F)F)=CC=N1 JTTOIYGKVCKBNW-UHFFFAOYSA-N 0.000 claims 1
- PUCXAAZLYORUSG-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-[4-(trifluoromethylsulfanyl)phenoxy]phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 PUCXAAZLYORUSG-UHFFFAOYSA-N 0.000 claims 1
- ZRHGDWMRFCDZHY-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-phenoxyphenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC=C1 ZRHGDWMRFCDZHY-UHFFFAOYSA-N 0.000 claims 1
- NTCDZWFHVBSFMK-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-pyridin-2-yloxyphenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC=N1 NTCDZWFHVBSFMK-UHFFFAOYSA-N 0.000 claims 1
- MJSYNNLNHBQPKS-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-pyridin-2-ylsulfanylphenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1SC1=CC=CC=N1 MJSYNNLNHBQPKS-UHFFFAOYSA-N 0.000 claims 1
- SZLNZRZZYLIKDT-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-(methylaminomethyl)-4-pyridin-3-yloxyphenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CN=C1 SZLNZRZZYLIKDT-UHFFFAOYSA-N 0.000 claims 1
- ABRACSMRTBYWFF-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[3-[(dimethylamino)methyl]-4-(6-methylpyridin-3-yl)oxyphenyl]methanone Chemical compound CN(C)CC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(C)N=C1 ABRACSMRTBYWFF-UHFFFAOYSA-N 0.000 claims 1
- RWTPCDGKWMQRGA-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(2,3-dichlorophenoxy)-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC(Cl)=C1Cl RWTPCDGKWMQRGA-UHFFFAOYSA-N 0.000 claims 1
- LNWOQXOSMRBZBN-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(2,3-difluorophenoxy)-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC(F)=C1F LNWOQXOSMRBZBN-UHFFFAOYSA-N 0.000 claims 1
- ORIYQOUBEPERFH-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(2-fluorophenoxy)-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC=C1F ORIYQOUBEPERFH-UHFFFAOYSA-N 0.000 claims 1
- ANDYBNKRXGVQGP-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 ANDYBNKRXGVQGP-UHFFFAOYSA-N 0.000 claims 1
- PIVRFBAMCBQCDZ-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(3-fluorophenoxy)-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC(F)=C1 PIVRFBAMCBQCDZ-UHFFFAOYSA-N 0.000 claims 1
- DIKWOUATAGYMJW-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(3-methoxyphenoxy)-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC(OC)=C1 DIKWOUATAGYMJW-UHFFFAOYSA-N 0.000 claims 1
- LOMPCAVUANIGGY-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(4-fluorophenoxy)-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(F)C=C1 LOMPCAVUANIGGY-UHFFFAOYSA-N 0.000 claims 1
- OWBACNIWWBKBHC-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(morpholin-4-ylmethyl)-3-pyridin-3-yloxyphenyl]methanone Chemical compound C=1C=C(CN2CCOCC2)C(OC=2C=NC=CC=2)=CC=1C(=O)N(CC1)CCCN1C1CC1 OWBACNIWWBKBHC-UHFFFAOYSA-N 0.000 claims 1
- KMHZJBNYIWFWAY-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-(piperidin-1-ylmethyl)-3-pyridin-3-yloxyphenyl]methanone Chemical compound C=1C=C(CN2CCCCC2)C(OC=2C=NC=CC=2)=CC=1C(=O)N(CC1)CCCN1C1CC1 KMHZJBNYIWFWAY-UHFFFAOYSA-N 0.000 claims 1
- NURMXNUIQVJHSR-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[4-[(3,4-dichlorophenyl)methoxy]-3-(methylaminomethyl)phenyl]methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OCC1=CC=C(Cl)C(Cl)=C1 NURMXNUIQVJHSR-UHFFFAOYSA-N 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 1
- XTALQXXENKAGEX-UHFFFAOYSA-N 2-[4-(4-cyclopropyl-1,4-diazepane-1-carbonyl)-2-(methylaminomethyl)phenoxy]benzonitrile Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC=C1C#N XTALQXXENKAGEX-UHFFFAOYSA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- UWCGILLDYHOPEU-UHFFFAOYSA-N 3-[4-(4-cyclopropyl-1,4-diazepane-1-carbonyl)-2-(methylaminomethyl)phenoxy]benzonitrile Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC(C#N)=C1 UWCGILLDYHOPEU-UHFFFAOYSA-N 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- NLHDACBKUHRZEW-UHFFFAOYSA-N 4-[4-(4-cyclopropyl-1,4-diazepane-1-carbonyl)-2-(methylaminomethyl)phenoxy]benzonitrile Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(C#N)C=C1 NLHDACBKUHRZEW-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 206010013578 Dizziness postural Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000025535 REM sleep behavior disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- FSAUBGQRVAOUAE-UHFFFAOYSA-N [3-(methylaminomethyl)-4-(4-methylsulfanylphenoxy)phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C(C)C)=CC=C1OC1=CC=C(SC)C=C1 FSAUBGQRVAOUAE-UHFFFAOYSA-N 0.000 claims 1
- BUDXPODSGXONSZ-UHFFFAOYSA-N [3-(methylaminomethyl)-4-[4-(trifluoromethyl)phenoxy]phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C(C)C)=CC=C1OC1=CC=C(C(F)(F)F)C=C1 BUDXPODSGXONSZ-UHFFFAOYSA-N 0.000 claims 1
- GTKIXXYJXPDXOP-UHFFFAOYSA-N [3-[(cyclopropylamino)methyl]-4-(3,4-dichlorophenoxy)phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound C1=C(Cl)C(Cl)=CC=C1OC1=CC=C(C(=O)N2CCN(CCC2)C2CC2)C=C1CNC1CC1 GTKIXXYJXPDXOP-UHFFFAOYSA-N 0.000 claims 1
- FUZGNJYLLVRAMT-UHFFFAOYSA-N [3-[(cyclopropylamino)methyl]-4-(3,4-dichlorophenoxy)phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=C1CNC2CC2)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 FUZGNJYLLVRAMT-UHFFFAOYSA-N 0.000 claims 1
- NQRPBAJKYSQQRJ-UHFFFAOYSA-N [3-[(cyclopropylamino)methyl]-4-pyridin-3-yloxyphenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound C=1C=C(OC=2C=NC=CC=2)C(CNC2CC2)=CC=1C(=O)N(CC1)CCCN1C1CC1 NQRPBAJKYSQQRJ-UHFFFAOYSA-N 0.000 claims 1
- QYNGZGASLPHHCL-UHFFFAOYSA-N [3-phenylmethoxy-4-(piperidin-1-ylmethyl)phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=C1OCC=2C=CC=CC=2)=CC=C1CN1CCCCC1 QYNGZGASLPHHCL-UHFFFAOYSA-N 0.000 claims 1
- HYGYMUXCJFZKTO-UHFFFAOYSA-N [4-(2-chloro-4-fluorophenoxy)-3-(methylaminomethyl)phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(F)C=C1Cl HYGYMUXCJFZKTO-UHFFFAOYSA-N 0.000 claims 1
- MAQNQIWTRFNBKG-UHFFFAOYSA-N [4-(2-chloro-4-fluorophenoxy)-3-(methylaminomethyl)phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C(C)C)=CC=C1OC1=CC=C(F)C=C1Cl MAQNQIWTRFNBKG-UHFFFAOYSA-N 0.000 claims 1
- DTGQAURGKWOQAA-UHFFFAOYSA-N [4-(3,4-dichlorophenoxy)-3-(methylaminomethyl)phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C(C)C)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 DTGQAURGKWOQAA-UHFFFAOYSA-N 0.000 claims 1
- IIIHKNDFLNZYSC-UHFFFAOYSA-N [4-(3-chloro-2-fluorophenoxy)-3-(methylaminomethyl)phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC(Cl)=C1F IIIHKNDFLNZYSC-UHFFFAOYSA-N 0.000 claims 1
- GMTUNRCWXIGLSX-UHFFFAOYSA-N [4-(3-chloro-4-fluorophenoxy)-3-(methylaminomethyl)phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(F)C(Cl)=C1 GMTUNRCWXIGLSX-UHFFFAOYSA-N 0.000 claims 1
- QUZXTJYADOYRDB-UHFFFAOYSA-N [4-(3-chlorophenoxy)-3-(methylaminomethyl)phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=CC(Cl)=C1 QUZXTJYADOYRDB-UHFFFAOYSA-N 0.000 claims 1
- RGPYWCVMPLKNBH-UHFFFAOYSA-N [4-(3-chlorophenoxy)-3-(methylaminomethyl)phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C(C)C)=CC=C1OC1=CC=CC(Cl)=C1 RGPYWCVMPLKNBH-UHFFFAOYSA-N 0.000 claims 1
- KTXYACXXINQJMM-UHFFFAOYSA-N [4-(4-chloro-2-fluorophenoxy)-3-(methylaminomethyl)phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(Cl)C=C1F KTXYACXXINQJMM-UHFFFAOYSA-N 0.000 claims 1
- LUJLISGGFLGFKZ-UHFFFAOYSA-N [4-(4-chlorophenoxy)-3-(methylaminomethyl)phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(Cl)C=C1 LUJLISGGFLGFKZ-UHFFFAOYSA-N 0.000 claims 1
- CVFUNUQUAWLUGT-UHFFFAOYSA-N [4-(4-chlorophenoxy)-3-(methylaminomethyl)phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C(C)C)=CC=C1OC1=CC=C(Cl)C=C1 CVFUNUQUAWLUGT-UHFFFAOYSA-N 0.000 claims 1
- QSYJJNOIIJRBCL-UHFFFAOYSA-N [4-(4-chlorophenoxy)-3-(methylaminomethyl)phenyl]-(5-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methanone Chemical compound CNCC1=CC(C(=O)N2C3CC(N(C3)C(C)C)C2)=CC=C1OC1=CC=C(Cl)C=C1 QSYJJNOIIJRBCL-UHFFFAOYSA-N 0.000 claims 1
- PYHIXIXROUXPRF-UHFFFAOYSA-N [4-(4-chlorophenoxy)-3-[(cyclopropylamino)methyl]phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1OC1=CC=C(C(=O)N2CCN(CCC2)C2CC2)C=C1CNC1CC1 PYHIXIXROUXPRF-UHFFFAOYSA-N 0.000 claims 1
- XQIMZDXBCQKPGH-UHFFFAOYSA-N [4-(4-chlorophenoxy)-3-[(cyclopropylamino)methyl]phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=C1CNC2CC2)=CC=C1OC1=CC=C(Cl)C=C1 XQIMZDXBCQKPGH-UHFFFAOYSA-N 0.000 claims 1
- WVDZKFHNTDXNHW-UHFFFAOYSA-N [4-(4-chlorophenoxy)-3-[[cyclopropyl(methyl)amino]methyl]phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound C1CC1N(C)CC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1OC1=CC=C(Cl)C=C1 WVDZKFHNTDXNHW-UHFFFAOYSA-N 0.000 claims 1
- LMZUKDCJCWRZBR-UHFFFAOYSA-N [4-(4-chlorophenyl)sulfanyl-3-(methylaminomethyl)phenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C2CC2)=CC=C1SC1=CC=C(Cl)C=C1 LMZUKDCJCWRZBR-UHFFFAOYSA-N 0.000 claims 1
- RWOGAYUMNHAMLE-UHFFFAOYSA-N [4-(4-chlorophenyl)sulfanyl-3-(methylaminomethyl)phenyl]-(5-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methanone Chemical compound CNCC1=CC(C(=O)N2C3CC(N(C3)C(C)C)C2)=CC=C1SC1=CC=C(Cl)C=C1 RWOGAYUMNHAMLE-UHFFFAOYSA-N 0.000 claims 1
- DPWSSZGTQMQUTM-UHFFFAOYSA-N [4-[(cyclopropylamino)methyl]-3-pyridin-3-yloxyphenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound C=1C=C(CNC2CC2)C(OC=2C=NC=CC=2)=CC=1C(=O)N(CC1)CCCN1C1CC1 DPWSSZGTQMQUTM-UHFFFAOYSA-N 0.000 claims 1
- URRKXZIAXKKOAU-UHFFFAOYSA-N [4-[(dimethylamino)methyl]-3-(2,6-dimethylpyridin-3-yl)oxyphenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C1=CC=C(CN(C)C)C(OC=2C(=NC(C)=CC=2)C)=C1 URRKXZIAXKKOAU-UHFFFAOYSA-N 0.000 claims 1
- PKFXVENTYDHHPZ-UHFFFAOYSA-N [4-[4-chloro-3-(trifluoromethyl)phenoxy]-3-(methylaminomethyl)phenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound CNCC1=CC(C(=O)N2CCN(CCC2)C(C)C)=CC=C1OC1=CC=C(Cl)C(C(F)(F)F)=C1 PKFXVENTYDHHPZ-UHFFFAOYSA-N 0.000 claims 1
- OZMICXPEMZDZPC-UHFFFAOYSA-N [4-[[2-(hydroxymethyl)morpholin-4-yl]methyl]-3-phenoxyphenyl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=C1OC=2C=CC=CC=2)=CC=C1CN1CC(CO)OCC1 OZMICXPEMZDZPC-UHFFFAOYSA-N 0.000 claims 1
- VDNZYSMPDQTVEA-UHFFFAOYSA-N [4-[[bis(2-methoxyethyl)amino]methyl]-3-phenylmethoxyphenyl]-(4-cyclopropyl-1,4-diazepan-1-yl)methanone Chemical compound COCCN(CCOC)CC1=CC=C(C(=O)N2CCN(CCC2)C2CC2)C=C1OCC1=CC=CC=C1 VDNZYSMPDQTVEA-UHFFFAOYSA-N 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 230000002060 circadian Effects 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001165 modafinil Drugs 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000003175 retinitis pigmentosa 30 Diseases 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000037321 sleepiness Effects 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 C*C(N1CCNCCC1)=O Chemical compound C*C(N1CCNCCC1)=O 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80616706P | 2006-06-29 | 2006-06-29 | |
| PCT/US2007/071739 WO2008002818A1 (en) | 2006-06-29 | 2007-06-21 | Substituted aminomethyl benzamide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009542708A JP2009542708A (ja) | 2009-12-03 |
| JP2009542708A5 true JP2009542708A5 (enExample) | 2010-08-05 |
Family
ID=38670055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518465A Withdrawn JP2009542708A (ja) | 2006-06-29 | 2007-06-21 | 置換アミノメチルベンズアミド化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080045508A1 (enExample) |
| EP (1) | EP2046747A1 (enExample) |
| JP (1) | JP2009542708A (enExample) |
| CN (1) | CN101511790A (enExample) |
| AU (1) | AU2007265240A1 (enExample) |
| CA (1) | CA2656083A1 (enExample) |
| WO (1) | WO2008002818A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5069907B2 (ja) * | 2003-09-17 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 縮合複素環式化合物 |
| US7598255B2 (en) * | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP2011512359A (ja) * | 2008-02-14 | 2011-04-21 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物 |
| JP2011518130A (ja) * | 2008-04-02 | 2011-06-23 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144309A0 (en) * | 1999-02-23 | 2002-05-23 | Pfizer Prod Inc | Monoamine reuptake inhibitors for treatment of cns disorders |
| GB0007884D0 (en) * | 2000-03-31 | 2000-05-17 | Pfizer Ltd | Diphenyl ether compounds useful in therapy |
| JP2004507523A (ja) * | 2000-08-31 | 2004-03-11 | ファイザー・インク | 選択的セロトニン再取込み阻害剤としてのフェノキシベンジルアミン誘導体 |
| EP1831173B1 (en) * | 2004-12-17 | 2011-01-26 | Janssen Pharmaceutica NV | Tetrahydroisoquinoline compounds for treatment of cns disorders |
| DE602006002894D1 (de) * | 2005-06-17 | 2008-11-06 | Janssen Pharmaceutica Nv | Naphthyridinverbindungen |
| US7754882B2 (en) * | 2005-06-17 | 2010-07-13 | Janssen Pharmaceutica Nv | Hexahydro-pyrrolo-isoquinoline compounds |
-
2007
- 2007-06-21 CA CA002656083A patent/CA2656083A1/en not_active Abandoned
- 2007-06-21 CN CNA2007800323970A patent/CN101511790A/zh active Pending
- 2007-06-21 EP EP07798863A patent/EP2046747A1/en not_active Withdrawn
- 2007-06-21 JP JP2009518465A patent/JP2009542708A/ja not_active Withdrawn
- 2007-06-21 WO PCT/US2007/071739 patent/WO2008002818A1/en not_active Ceased
- 2007-06-21 AU AU2007265240A patent/AU2007265240A1/en not_active Abandoned
- 2007-06-21 US US11/766,153 patent/US20080045508A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009542708A5 (enExample) | ||
| JP2009544579A5 (enExample) | ||
| CN103025721B (zh) | 吡啶甲酰胺和嘧啶-4-甲酰胺化合物、其制备方法以及含有该化合物的药物组合物 | |
| RU2309953C2 (ru) | Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе | |
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| US8592416B2 (en) | Isoquinolin-1 (2H)-one derivatives as PARP-1 inhibitors | |
| JP2011511001A5 (enExample) | ||
| RU2009136330A (ru) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора | |
| JP2018530571A5 (enExample) | ||
| JP2009541216A5 (enExample) | ||
| HRP20161121T1 (hr) | Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost | |
| JO2482B1 (en) | Amide compounds by replacement | |
| HRP20230201T1 (hr) | Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste | |
| RU2016116533A (ru) | Новые соединения и композиции для ингибирования nampt | |
| CA2527933A1 (en) | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | |
| JP2009542707A5 (enExample) | ||
| MX2012004662A (es) | Metodos de administracion de una terapia con pirfenidona. | |
| JP2007519754A5 (enExample) | ||
| JP2008502614A5 (enExample) | ||
| CA2622760A1 (en) | Cyclopropyl amines as modulators of the histamine h3 receptor | |
| JP6106182B2 (ja) | Ｐａｒｐ−１阻害剤としての３−フェニル−イソキノリン−１（２ｈ）−オン誘導体 | |
| JP2002525280A5 (enExample) | ||
| JP2005504725A5 (enExample) | ||
| CN1261358A (zh) | 抑制血管生成的5－取代的－1,2,4－噻二唑衍生物 | |
| JP2008516959A5 (enExample) |